BioCryst Pharmaceuticals BCRX Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance.
The official record: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent?
- BioCryst Pharmaceuticals (BCRX) reported effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent of -20% in Q4 2025.
- What does effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent mean?
- Represents the percentage point impact on the effective tax rate resulting from adjustments to the valuation allowance for deferred tax assets. It quantifies how changes in the assessment of future tax asset realization affect the overall tax burden. This metric helps investors understand the volatility of the company's tax position relative to its earnings.